Aiforia releases a new CE-IVD-marked clinical AI solution for breast cancer diagnostics
Aiforia Breast Cancer Grading AI solution is a part of the Aiforia Breast Cancer Suite, which also includes CE-IVD marked AI models for breast cancer biomarkers and the Aiforia Clinical Suite Viewer.
26 Jun 2025
Aiforia Technologies Plc launches a new CE-IVD marked clinical AI solution for breast cancer grading. Aiforia® Breast Cancer Grading AI solution is a part of the Aiforia® Breast Cancer Suite, which also includes CE-IVD marked AI models for breast cancer biomarkers and the Aiforia® Clinical Suite Viewer. This complete solution offers a fully digital cockpit for breast cancer diagnostics, supporting the entire diagnostic workflow.
The new CE-IVD marked AI solution automates breast cancer grading by supporting pathologists with the help of five separate AI models. It accurately identifies invasive carcinoma and ductal carcinoma in situ (DCIS). It also objectively detects and scores mitotic count, tubular formation, and nuclear pleomorphism, consistent with the Nottingham Grading System. This addresses the key challenges of manual grading, such as variability and time constraints.
“We are proud to announce the latest CE-IVD marked solution in our breast cancer diagnostics portfolio, making Aiforia® Breast Cancer Suite the most comprehensive AI toolkit on the market. The new solution brings substantial time savings to the pathologists when reporting the histological grade and enhances diagnostic accuracy and consistency across cases, leading to increased confidence in clinical decision-making,” explains Jukka Tapaninen, CEO of Aiforia Technologies.